Oral Resveratrol And Calcium Fructoborate Supplementation In Subjects With Stable Angina Pectoris: Effects On Lipid Profiles, Inflammation Markers, And Quality Of Life

Effect Decrease
Values pg/ml. Resveratrol: before 674 ± 192, after 271 ± 137 (−59.7%). Combination: before 662 ± 238, after 228 ± 84 (−65.5%). Boron: before 684 ± 151, after 324 ± 102 (−52.6%). Control: before 671 ± 218, after 514 ± 207 (−23.3%).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 116
Sex Both Genders
Notes for this study:
In a randomized, double-blind, active-controlled trial, 116 participants with stable angina were allocated to take 20 mg/day of resveratrol, 20 mg/day of resveratrol with 112 mg/day (3 mg of boron) of calcium fructoborate, 112 mg/day of calcium fructoborate, or their usual medical care for 2 months.

The primary outcomes were markers of inflammation and lipids. The addition of boron to resveratrol didn't appear to make a difference for c-reactive protein, though boron by itself saw the greatest reduction. NT-proBNP was reduced the most in the combination group, and boron on its own led to a notable reduction compared with control. Total cholesterol was reduced the most in the resveratrol group, though there was a slight reduction compared with control in the boron-only group. The boron-only group saw the greatest reduction in LDL and an increase in HDL, while the combination was less effective than resveratrol alone. Triglycerides were reduced most in the resveratrol group, with a similar reduction in the boron-only group.

Angina episodes were reduced most in the combination group, and the boron-only group saw a greater reduction than the control group, and the need for nitroglycerin was reduced similarly.